All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your MPN Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Ropeginterferon alfa-2b in patients with early/lower-risk primary MF
|
Pegylated interferon alfa is recommended for the treatment of patients with lower-risk PMF who are symptomatic, based on phase II non-randomized studies and expert opinion. Ropeg shows promise in achieving durable hematologic responses, including normalization of blood counts and control of PMF-related symptoms, and has the potential to modify disease progression. In a recent publication in Annals of Hematology, Abu‑Zeinah et al. outline a planned randomized phase III trial designed to assess the efficacy and safety of ropeg in patients with early/lower-risk PMF.1
|
| Key learnings |
|
This new phase III trial (NCT06468033) will evaluate the efficacy and safety of ropeg in 150 patients with early/lower-risk PMF, randomized 2:1 to receive either ropeg or placebo. |
|
Co-primary endpoints include clinically relevant complete hematologic response and symptom endpoint (no progression of clinical symptoms) at 56 weeks. |
|
Secondary endpoints include PFS/EFS, molecular response in driver or relevant coexisting gene mutations, bone marrow response, and safety. |
|
The study will provide important data for the treatment of early/lower-risk PMF for which an anti-clonal, disease-modifying agent is highly needed. |
|
Ropeg could address a critical unmet need in this patient population by offering a safe and effective option that reduces thrombosis risk and delays disease progression. |
Abbreviations: EFS, event-free survival; MF, myelofibrosis; MPN, myeloproliferative neoplasm; PFS, progression-free survival; PMF, primary myelofibrosis; ropeg, ropeginterferon alfa-2b.
- Abu-Zeinah G, Qin A, Gill H, Komatsu N, et al. A randomized, double-blind, placebo-controlled phase 3 study to assess efficacy and safety of ropeginterferon alfa-2b in patients with early/lower-risk primary myelofibrosis. Ann Hematol. 2024;103(9):3573-3583. DOI: 10.1007/s00277-024-05912-8.
Your opinion matters
21 votes - 25 days left ...
Newsletter
Subscribe to get the best content related to MPN delivered to your inbox